

Potential association of prolonged patient interval and advanced anatomic stage in breast cancer patients in the area affected by the 2011 triple disaster in Fukushima, Japan

Retrospective observational study

Akihiko Ozaki, MD, PhD^{a,b,*}, Sawano Toyoaki, MD^{a,c,d}, Manabu Tsukada, MD^e, Yuki Shimada, MD^f, Ayumu Kawamoto, MD^g, Ji-Wei Wang, PhD^h, Divya Bhandari, MSHⁱ, Masaharu Tsubokura, MD, PhD^{a,d}, Hiromichi Ohira, MD^e

Abstract

For five years after the 2011 triple disaster (earthquake, tsunami, and nuclear disaster) in Japan, the proportion of patients with undiagnosed symptomatic breast cancer remained elevated in the coastal area of Fukushima. These individuals experienced a prolonged interval from first symptom recognition to initial medical consultation (hereafter referred to as the *patient interval*). We aimed to investigate how this prolonged patient interval affected disease staging.

Using patient records, we retrospectively extracted females with newly and pathologically diagnosed breast cancer who initially presented to Minamisoma Municipal General Hospital from March 2011 to March 2016. We estimated the proportion with advanced-stage disease (III, IV) according to the patient interval duration (<3 months, 3–12 months, and 12 months plus). A cut-off patient interval value was determined based on the previous evidence with regards to impacts on survival prospects. Logistic regression approaches were used to fulfill the study outcome.

The proportion of patients with advanced-stage disease was 10.3% for <3months (7/68), 18.2% for 3-12months (2/11), and 66.7% for more than 12months (12/18). We found a similar trend using the multivariate logistic regression analyses.

Prolongation of the patient interval was associated with advanced-stage disease among female patients with breast cancer.

Abbreviation: MMGH = Minamisoma Municipal General Hospital.

Keywords: breast neoplasms, Fukushima nuclear accident, help-seeking behavior, neoplasm staging

1. Introduction

Early diagnosis and treatment are the cornerstones of breast cancer management. Although awareness programs have led to a high uptake of breast cancer screening in high-income countries such as the US^[1] and a majority of European countries,^[2] a large proportion of breast cancer patients are diagnosed only after they recognize relevant symptoms (e.g., breast lumps and/or nipple discharge). In Japan, 51.7% of the patients newly diagnosed in

Editor: Flavio Palmieri.

Akihiko Ozaki receives personal fees from MNES Inc, outside the submitted work. Other authors did not declare any conflicts of interest.

Data access statement: Data: The datasets analyzed during the present study are available from the corresponding author on reasonable request.

Institutional review board statement: We obtained ethical clearance from the Ethics Committee at MMGH.

The datasets generated during and/or analyzed during the present study are not publicly available, but are available from the corresponding author on reasonable request.

^a Research Center for Community Health, Minamisoma Municipal General Hospital, Minamisoma, Fukushima, Japan, ^b Department of Breast Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima, Japan, ^c Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima, Japan, ^d Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan, ^e Department of Surgery, Minamisoma Municipal General Hospital, Minamisoma, Fukushima, Japan, ^f Department of Neurosurgery, Minamisoma Municipal General Hospital, Minamisoma, Fukushima, Japan, ^g Faculty of Medicine, University of Szeged, Szeged, Hungary, ^h Key Lab of Health Technology Assessment of Ministry of Health, School of Public Health, Fudan University, Shanghai, China, ⁱ Medical Governance Research Institute, Minato-City, Tokyo, Japan.

* Correspondence: Akihiko Ozaki, Research Center for Community Health, Minamisoma Municipal General Hospital, 2-54-6 Takamicho, Haramachi, Minamisoma, Fukushima, Japan (e-mail: aozaki-tky@umin.ac.jp).

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Ozaki A, Toyoaki S, Tsukada M, Shimada Y, Kawamoto A, Wang JW, Bhandari D, Tsubokura M, Ohira H. Potential association of prolonged patient interval and advanced anatomic stage in breast cancer patients in the area affected by the 2011 triple disaster in Fukushima, Japan: Retrospective observational study. Medicine 2021;100:32(e26830).

Received: 20 March 2021 / Received in final form: 7 July 2021 / Accepted: 16 July 2021 http://dx.doi.org/10.1097/MD.00000000026830

This study is supported by grants from the Toyota Foundation (D17-R-0540). The funding sponsors had no role in the design of the study, in the collection, analyses or interpretation of data; in the writing of the manuscript or in the decision to publish the results.

2017 presented with symptoms suggestive of breast cancer.^[3] Further, some of these patients put off their first medical consultation even when they recognized their symptoms.^[4,5] While reasons for these delayed presentations should be explored individually, various patient-level and external factors are reportedly associated with this phenomenon.^[4,6,7]

Among these external factors, disasters and crises have become much more prominent as the recent coronavirus (COVID-19) pandemic could potentially shift priorities onto individuals with more urgent symptoms than those suggestive of breast cancer.^[8] Indeed, a similar phenomenon occurred during the 2011 triple disaster in Japan (earthquake, tsunami, and the Fukushima Daiichi Nuclear Power Plant Disaster); in the So-so District, the northen coatral area of Fukushima, Japan, which houses the power plant, the proportion of undiagnosed symptomatic breast cancer patients who experienced prolonged patient intervals (the period from first symptom recognition to initial medical consultation) remained elevated for five years after the disaster when compared to the pre-disaster baseline.^[9] One major plausible reason for this phenomenon is fluctuating social and family support due to mass evacuations following the disaster.^{[9–}

¹² However, little is known about how this prolonged patient interval has influenced survival prospects. In breast cancer patients, anatomic staging has been an important surrogate marker of survival prospects despite the recent emergence of prognostic staging,^[13] and this is also the case with recent Japanese breast cancer patients.^[14] Therefore, we evaluated how a prolonged patient interval affected anatomic staging among post-disaster undiagnosed symptomatic breast cancer patients in the area affected by the 2011 Fukushima triple disaster.

2. Methods

2.1. Study setting and participants

This is a secondary analysis of our previously published work that retrospectively compared the patient interval between preand post-disaster undiagnosed symptomatic breast cancer patients in the So-so District, Fukushima.^[9] We considered all 97 post-disaster breast cancer patients who were included in our previous study. In short, all patients were women with breast cancer diagnoses based on pathological findings, and all of them had continuously lived in the So-so District before and after the disaster. These patients initially presented to Minamisoma Municipal General Hospital (MMHG), located in Minamisoma City, the largest municipality in the So-so District, Fukushima, from March 11, 2011 to March 10, 2016.^[9] In our previous work, we considered Watanabe Hospital, which is also in Minamisoma City, as the other study setting, but we excluded it in the present analysis due to its discontinuation of inpatient functions after the disaster.^[9]

2.2. Analytical data

We retrospectively collected the sociodemographic and clinical characteristics of the patients from medical records stored in the MMGH, which were summarized in our previous study.^[9] Following our previous study^[9] and other evidence on associations between patient interval and survival prospects of breast cancer,^[4,15–17] we categorized patient intervals into three groups: less than three months, three to twelve months, and twelve months or more. In general, patient intervals of three months or longer are believed to impair survival prospects of breast cancer patients.^[15,16] Further, a patient interval of twelve months or longer can be observed in resource-limited settings such as in disaster aftermaths^[9,11] and low-and middle-income countries, with extensive impacts on survival prospects of breast cancer patients.^[4,15–17]

We diagnosed the patients according to anatomic staging as defined by the American Joint Committee on Cancer Eight Edition^[18] and categorized them into two groups: advanced stage (Stage III, IV) and otherwise (Stage 0, I, or II). Categorification of other variables mostly followed our previous study.^[9]

2.3. Data analysis

For this study, we performed two analyses. First, we estimated the proportion of patients diagnosed with advanced cancer in





Table 1

Univariate and multivariate logistic regression analyses for diagnosis of advanced cancer.

Variable Odds Ratio (95% CI) P-value Odds ratio (95% CI) P-value Length or platent interval Less than three months 1.00	Variable	Univariate analysis		Multivariate analysis	
large of patient interval 100 45 1.06 (0.18-6.19) 95 Twee months or longer 17.43 (4.97-61.07) <.001 22.77 (5.19-99.82) <.001 There months or longer 10.0 (0.25-0.09) .90 <t< th=""><th>Odds Ratio (95% CI)</th><th>P-value</th><th>Odds ratio (95% CI)</th><th><i>P</i>-value</th></t<>		Odds Ratio (95% CI)	P-value	Odds ratio (95% CI)	<i>P</i> -value
Liss from three norths 1.00 Three to kinkle months 1.94 (0.35-10.62) .45 1.06 (0.18-6.19) .95 Twoke months or longor 17.43 (4.97-61.07) .001 22.77 (5.19-90.82) .001 Betace from concernetar 1.01 (0.33-1.03) .90 .90 .90 Referent from other medical providers 0.73 (0.28-2.09) .55 .55 .55 Days from initial medical consultation to first examination 1.00 .00 .22 .45 .46 Votinatity execution zone of 25 so District 1.00 .00 .22 .46 .46 -50 1.06 .035 (0.28-2.68) .34 .49 .40 .40 .42 .42 .42 .42 .46 .40 .40 .40 .40 .40 .40 .40 .40 .40 .42 .42 .42 .42 .43 .42 .42 .42 .42 .42 .42 .43 .43 .40 .40 .40 .40 .40 .40 .40 .40 </td <td>Length of patient interval</td> <td></td> <td></td> <td></td> <td></td>	Length of patient interval				
These bases models 194 (0.35-1082) 45 1.06 (0.18-6.19) 95 Detains from cancer center 1.01 (0.03-1.09) .00 .001 .	Less than three months	1.00			
Twelve months or longer 17,43 (4,97-61.07) <.001	Three to twelve months	1.94 (0.35-10.82)	.45	1.06 (0.18-6.19)	.95
Distance order 1.01 (0.93–1.09) .90 No 100 Yes 0.73 (0.25–2.09) .55 Dogs from initial medical providers 1.00 (1.00–1.00) .22 Residential address at the thring of the 2011 be disaster 1.00 .22 Non-monitation role of So-so Destrict 1.00 .22 Non-monitation role of So-so Destrict 1.00 .24 Non-monitation role of So-so Destrict 1.00 .24 Apple .250 (0.8–3.68) .54 Apple .250 (0.8–3.68) .54 Apple .251 (0.52–8.53) .29 Eraggation tall three job .21 (0.52–8.53) .29 Frequentiation role on so Destrict .20 .21 (0.52–8.53) No 1.00 .2-3 .20 Nother of taminy members .20 .20 .20 Or-In three medical providers .20 .20 .20 More of taminy members .20 .20 .20 Or-In tyme medication of the stream system control on taming were system control on taming system system control on taming system system c	Twelve months or longer	17.43 (4.97–61.07)	<.001	22.77 (5.19–99.82)	<.001
Refera from other medical providers No 100 Yes 073 025-209 55 Days from initial medical consultation to first examination 100 (1 00-1 00) 22 Particle and the thining of the 2011 triple disaster Poor-acatation zone 05-so District 075 021-2 09 060 Marciatory exacuation zone 0.55 (0.02-3 68) 5-4 Age -50] 100 (50-55] 185 042-8-12 42 (65- (50-55]) 185 042-8-12 42 (65- (50-55]) 185 042-8-12 42 (65- (50-55]) 185 042-8-12 42 (65- 000 000 Ne 0.00 Ne 0.00	Distance from cancer center	1.01 (0.93–1.09)	.90	× ,	
No 1.00 Yes 0.73 (0.25–2.09) 5.5 Days from initial medical consultation to first examination 1.00 (1.00–1.00) 2.2 Nam-exolutation zone of So-so District 1.00	Referral from other medical providers				
Yes 0.73 (0.25–2.09) 55 Days from itid redical consultation for the available address at the liming of the 2011 tiple disaster 1.00	No	1.00			
Days from initial medical consultation to first examination 1.00 (1.00-1.00) 22 Non-execution zone of So-so District 1.00	Yes	0.73 (0.25-2.09)	.55		
Residential address at the liming of the 2011 inplie disaster 1.00 Nonavacuation zone of So-so District 0.075 (0.21-2.60) 66 Mandatory exacuation zone 0.55 (0.08-368) .54 Age	Days from initial medical consultation to first examination	1.00 (1.00-1.00)	.22		
Non-execution zone 050-so District 1.00 Voluriday evacuation zone 0.55 (0.08-3.68) 54 Age -50] 1.00 50 (50-65) 1.85 (0.42-8.12) .42 (65- 2.11 (0.52-8.53) .29 Eragati in full-time job .00 .29 No 1.00 .20 Ves 0.76 (0.23-2.54) .65 Number of family members .20 0.41 (0.05-0.52) .20 More than 4 0.76 (0.13-3.14) .70 2-3 0.48 (0.15-1.50) .20 .40 More than 4 0.76 (0.13-3.14) .70 .40 Ves 1.00 .20 .40 .40 Ves 1.00 .20 .40 .40 .40 Ves 1.00 .20 .4	Residential address at the timing of the 2011 triple disaster				
Volumation zone 0.75 (0.21-2.68) .66 Age .57 .50 .54 -50] 1.00 .60 </td <td>Non-evacuation zone of So-so District</td> <td>1.00</td> <td></td> <td></td> <td></td>	Non-evacuation zone of So-so District	1.00			
Madatory execution zone 0.55 (0.08–3.68) 54 Age 1.00 - GO 1.85 (0.42–8.12) .42 (65– 2.11 (0.52–8.53) .29 Engaged in full-line job - - No 1.00 - Yes 0.76 (0.23–2.54) .65 Number of family members - - O-1 1.00 - 2-3 0.48 (0.15–1.50) .20 More than 4 0.76 (0.18–3.14) .70 Using with a partner 0.00 - No 1.00 .40 Yes 0.36 (0.13–1.03) .65 Symptom realization of lump .00 .65 No 1.00 .42 (0.09–1.94) .71 Yes 0.36 (0.13–1.03) .66 .65 Noma receptor .00 .62 .62 Noma receptor .00 .62 .62 .62 Patient with mid systemic disease 1.08 (0.38–3.07) .88 .86	Voluntary evacuation zone	0.75 (0.21-2.69)	.66		
Ape -50 1.00 (50-65] 1.65 (0.42-6.12) 4.2 (65- 2.11 (0.52-6.53) 2.9 Eragate in full-line job	Mandatory evacuation zone	0.55 (0.08-3.68)	.54		
-50] 1.00 (50-65) 1.68 (0.42-6.12) 42 (65-62) 2.11 (0.52-8.53) .29 Engaged in full-line job	Age				
(60-65) 1.85 (0.42-8.12) 42 (60- 2.11 (0.52-8.53) 29 Engaged in full-time job	-50]	1.00			
65- 2.11 (0.52-8.53) 29 Pagaget in full-time job 1.00 Yes 0.76 (0.23-2.54) 65 Number of family members 1.00 2-3 0-1 1.00 20 More than 4 0.76 (0.15-1.50) 20 More than 4 0.76 (0.15-3.14) .70 Living with a partner 00 1.00 Yes 1.00 (0.40-3.06) .85 Symptom realization of lump 0.00 .95 No 1.00 .95 No 1.00 .95 No 1.00 .95 Yes 0.36 (0.13-1.03) .66 Symptom realization of lump .90 .97 No 1.00 .98 Nos 1.01 (0.16-12.76) .76 Patient with null system Nord .90 .90 Nord healty patient 1.00 .90 Ody mass indek (kg/m ²) .90 .90 Patient with null systemic disease 1.08 (0.38-3.07) .88 <t< td=""><td>(50–65]</td><td>1.85 (0.42-8.12)</td><td>.42</td><td></td><td></td></t<>	(50–65]	1.85 (0.42-8.12)	.42		
Engaged in full-time job No 1.00 Yes 0.76 (0.23-2.54) 65 Number of family members 0-1 1.00 2-3 0.48 (0.15-1.50) 2.0 Amore than 4 0.76 (0.18-3.14) 7.0 Living with a partner No 1.00 Yes 1.00 40-3.05) 85 Living with children No 1.00 Yes 0.36 (0.13-1.03) 0.6 Symptom realization of lump No 1.00 Yes 0.36 (0.13-1.03) 0.6 Symptom realization of lump No 0.30 Yes 0.42 (0.09-1.94) 2.7 ASA physical classification system Normal healthy patient 1.00 Patient with swere systemic disease 1.08 (0.38-307) 88 Patient with swere systemic disease 1.01 (0.05-0.76 Patient with swere systemic disease 1.02 (0.09-1.94) 2.7 ASA physical classification system 1.00 Patient with swere systemic disease 1.08 (0.38-307) 88 Patient with swere systemic disease 1.01 (0.05-0.76) 5.0 Body mass index (kg/m ²) -25] 1.00 1.00 Yes 0.019 (0.05-0.76) 0.2 0.17 (0.03-0.96) 0.45 (30- 0.19 (0.05-0.76) 0.2 0.17 (0.03-0.96) 0.45 (30- 0.10 Yes 0.100 Yes 0.100 Yes 0.069 (0.14-3.45) 66 Family history of any cancer No 1.00 Yes 0.069 (0.17-1.31) 1.5	(65–	2.11 (0.52-8.53)	.29		
No 1.00 Yes 0.76 (0.23–2.54) .65 Number of family members 1 1.00 2–3 0.48 (0.15–1.50) .20 More than 4 0.76 (0.18–3.14) .70 Living with a partner .00 .20 No 1.00 .20 Yes 1.10 (0.40–3.06) .85 Living with children .00 .20 No 1.00 .20 Yes 0.36 (0.13–1.03) .66 Symptom realization of lump .00 .27 No 1.00 .27 Yes 0.42 (0.09–1.94) .27 Nagative 1.00 .27 Positive 0.42 (0.09–1.94) .27 Nagative 1.00 .20 Patient with nied systemic disease 1.71 (0.36–8.15) .50 Body mass index (kg/m) .25 .263 .72 1.40 (0.31–6.24) .66 Horisot ching breast disease 1.00 .20 .217 (0.0.3–0.36) .24 <	Engaged in full-time job				
Yes 0.76 $(0.23-2.54)$ 65 Number of family members 1 1.00 2-3 0.48 $(0.15-1.50)$.20 More than 4 0.76 $(0.18-3.14)$.70 Living with a partner 0 0 No 1.00	No	1.00			
Number of family members 0-1 1.00 2-3 0.48 (0.15-1.50) .20 More than 4 0.76 (0.18-3.14) .70 Living with a partner	Yes	0.76 (0.23–2.54)	.65		
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Number of family members				
2-3 0.48 (0.15-1.50) .20 More tha 4 0.76 (0.18-3.14) .70 Living with a partner .70 Yes 1.00 .85 Living with children .70 Yes 0.36 (0.13-1.03) .66 Sympton realization of lump .70 Yes 0.36 (0.13-1.03) .66 Sympton realization of sympton receptor .76 Nor the coeptor .76 Normal healthy patient .76 Positive 0.20 ASA physical classification system .76 Normal healthy patient 1.00 Patient with mild systemic disease 1.08 (0.38-3.07) Patient with mild systemic disease 1.71 (0.36-8.15) Body mass index (kg/m²) .50 Body mass index (kg/m²) .50 Body mass index (kg/m²) .50 Body mass index (kg/m²) .66 History of benign breast disease 1.00 Yes 1.89 (0.32-11.14) .48 Mamongraphy screening within two years .100 No 1.00 .56 Family history of any c	0–1	1.00			
More than 4 0.76 (0.18-3.14) .70 Living with a partner 00 00 Yes 1.00 (0.40-3.06) .85 Living with children 00 00 Yes 0.36 (0.13-1.03) .06 Symptom realization of lump 00	2–3	0.48 (0.15–1.50)	.20		
Living with a partner No 1.00 Yes 1.00 (.40–3.06) .85 Living with children No 1.00 Symptom realization of lump No 1.00 Yes 0.36 (0.13–1.03) .06 Symptom realization of lump No 1.00 Yes 0.41 (0.16–12.76) .76 Hormone receptor Negative 0.02 Positive 0.02 ASA physical classification system Normal healthy patient 1.00 Patient with mile systemic disease 1.08 (0.38–3.07) .88 Patient with severe systemic disease 1.08 (0.38–3.07) .88 Patient with severe systemic disease 1.01 (0.26–8.15) .50 Eody mass index (kg/m ²) -25] 1.00 (25–30] 0.19 (0.55–0.76) .02 0.17 (0.33–0.96) .045 (30– 0.81 (0.25–2.63) .72 1.40 (0.31–6.24) .66 History of benign breast disease No 1.00 Yes 1.89 (0.32–11.14) .48 Mammography screening within two years No 1.00 Yes 0.69 (0.14–3.45) .66 Family history of any cancer No 0.047 (0.17–1.31) .15	More than 4	0.76 (0.18–3.14)	.70		
No 1.00 Yes 1.00 (A0-3.06) .85 Living with children No 1.00 Yes 0.36 (0.13-1.03) .06 Symptom realization of lump No 1.00 Yes 0.36 (0.13-1.03) .06 Yes 1.00	Living with a partner				
Yes 1.10 (0.40–3.06) .85 Living with children .00 .00 Yes 0.36 (0.13–1.03) .06 Symptom realization of lump .00 .00 Yes 0.36 (0.13–1.03) .06 Symptom realization of lump .00 .00 Yes 1.41 (0.16–12.76) .76 Hormone receptor .00 .00 Negative 0.42 (0.09–1.94) .27 ASA physical classification system .00 .00 Patient with severe systemic disease 1.01 (0.36–8.15) .50 Body mass index (kg/m²) .00 .00 .045 _25] 1.00 (0.55–0.76) .02 (0.17 (0.03–0.96) (0.45 .66 History of benign breast disease .00 .22 1.40 (0.31–6.24) (0.66 .66 Wasser systemic disease 1.00 .02 0.17 (0.03–0.96) (0.45 .66 (30– 0.81 (0.25–2.63) .72 1.40 (0.31–6.24) (0.66 .66 Wasser systemic disease 0.00 .22 1.40 (0.31–6.24) (0.66 .66	No	1.00			
Living with children No 1.00 Yee 0.36 (0.13–1.03) .06 Symptom realization of lump 1.00 Yes 1.41 (0.16–12.76) .76 Hormone receptor 1.00 .76 Positive 0.42 (0.09–1.94) .27 ASA physical classification system 1.00 .76 Normal healthy patient 1.00 .76 Patient with mild systemic disease 1.08 (0.38–3.07) .88 Patient with severe systemic disease 1.08 (0.38–3.07) .88 Posting breast disease 1.00 .00 (25–30] 0.91 (0.25–0.76) .02 0.17 (0.03–0.96) .045 (30– 0.19 (0.52–2.63) .72 1.40 (0.31–6.24) .66 History of benign breast disease 1.00	Yes	1.10 (0.40–3.06)	.85		
No 1.00 Yes 0.36 (0.13-1.03) .06 Symptom realization of lump 1.00 .00 Yes 1.41 (0.16-12.76) .76 Hormone receptor .00 .00 Positive 0.42 (0.09-1.94) .27 ASA physical classification system .00 .01 Normal healthy patient 1.00 .00 Patient with severe systemic disease 1.08 (0.38-3.07) .88 Patient with severe systemic disease 1.01 (0.36-8.15) .50 Body mass index (kg/m²) .00 .00 .01 -25 1.00 1.00 .045 (30- 0.19 (0.05-0.76) .02 0.17 (0.03-0.96) .045 (30- 0.19 (0.05-2.63) .72 1.40 (0.31-6.24) .66 History of beingn breast disease 1.89 (0.32-11.14) .48 .48 .48 .48 Mamography screening within two years .00 .00 .48 .48 .48 No 0.69 (0.14-3.45) .66 .66 .69	Living with children	4.00			
Yes 0.36 (0.13-1.03) .06 Symptom realization of lump .00 .00 Yes 1.00 .76 Hormone receptor .76 .76 Negative 0.42 (0.09-1.94) .27 ASA physical classification system .00 .71 Positive 0.42 (0.09-1.94) .27 ASA physical classification system .00 .71 Patient with mild systemic disease 1.08 (0.38-3.07) .88 Patient with severe systemic disease 1.03 (0.6-8.15) .50 Body mass index (kg/m²) .22 .100 .40 (0.31-6.24) .66 (25-30] 0.19 (0.05-0.76) .02 0.17 (0.03-0.96) .045 (30- 0.81 (0.25-2.63) .72 1.40 (0.31-6.24) .66 History of benign breast disease .00 .22 .17 (0.03-0.96) .045 (30- 0.81 (0.25-2.63) .72 1.40 (0.31-6.24) .66 History of benign breast disease .88 .89 .88 No 1.00 .22	No	1.00	00		
Symptom realization or lump 1.00 Yes 1.41 (0.16–12.76) .76 Hormone receptor 1.00 Positive 0.42 (0.0–1.94) .27 ASA physical classification system 1.00 Patient with mild systemic disease 1.08 (0.38–3.07) .88 Patient with severe systemic disease 1.01 (0.36–8.15) .50 Body mass index (kg/m ²) - - -25] 1.00 1.00 (25–30] 0.19 (0.05–0.76) .02 0.17 (0.03–0.96) .045 (30– 0.81 (0.25–2.63) .72 1.40 (0.31–6.24) .66 History of benign breast disease 1.00 Yes 1.69 (0.3–11.14) .48 Marmmorgaphy screening within two years 1.00 Yes 0.69 (0.14–3.45) .66 Family history of any cancer 1.00 Yes 0.69 (0.14–3.45) .66 Yes 0.69 (0.14–3.45) .66 Yes Yes .60 Yes 0.47 (0.17–1.31) .15 .50 .50	Yes	0.36 (0.13–1.03)	.06		
No 1.00 Yes 1.41 (0.16–12.76) .76 Hormone receptor	Symptom realization of lump	1.00			
Tes 1.41 (0.16-12.76) .76 Hormone receptor .100 Positive 0.42 (0.09-1.94) .27 ASA physical classification system .100 Patient with mild systemic disease 1.08 (0.38-3.07) .88 Patient with severe systemic disease 1.71 (0.36-8.15) .50 Body mass index (kg/m ²) .27 -25] 1.00 1.00 (25-30] 0.19 (0.05-0.76) .02 0.17 (0.03-0.96) .045 (30- 0.81 (0.25-2.63) .72 1.40 (0.31-6.24) .66 No 1.00 Yes 1.89 (0.32-11.14) .48 Marmography screening within two years .069 (0.14-3.45) .66 Family history of any cancer .00 Yes 0.69 (0.14-3.45) .66 Family history of any cancer .00 .00 Yes .047 (0.17-1.31) .15	NO		70		
Induction and tectsplot Negative 1.00 Positive 0.42 (0.09–1.94) .27 ASA physical classification system 1.00 Patient with mild systemic disease 1.08 (0.38–3.07) .88 Patient with severe systemic disease 1.71 (0.36–8.15) .50 Body mass index (kg/m ²) -25] 1.00 1.00 -25, -30] 0.19 (0.05–0.76) .02 0.17 (0.03–0.96) .045 (30– 0.81 (0.25–2.63) .72 1.40 (0.31–6.24) .66 History of benign breast disease 1.89 (0.32–11.14) .48	Yes	1.41 (0.16-12.76)	.70		
Negative 1.00 Positive 0.42 (0.09–1.94) .27 ASA physical classification system 1.00 Patient with mild systemic disease 1.08 (0.38–3.07) .88 Patient with severe systemic disease 1.71 (0.36–8.15) .50 Body mass index (kg/m ²) 1.00 1.00 -25] 1.00 1.00 (25–30] 0.19 (0.05–0.76) .02 0.17 (0.03–0.96) .045 (30– 0.81 (0.25–2.63) .72 1.40 (0.31–6.24) .66 History of benign breast disease 1.89 (0.32–11.14) .48	Hormone receptor	1.00			
Positive 0.42 (0.09–1.94) .27 ASA physical classification system .00 Patient with mild systemic disease 1.08 (0.38–3.07) .88 Patient with severe systemic disease 1.71 (0.36–8.15) .50 Body mass index (kg/m²) .21 .21 -25] 1.00 1.00 (25–30] 0.19 (0.05–0.76) .02 0.17 (0.03–0.96) .045 (30– 0.81 (0.25–2.63) .72 1.40 (0.31–6.24) .66 History of benign breast disease 1.00 .21 .21 .22 .21 .20 .21 .20 .21 .20 .21 .21 .21 .21 .22 .21 .21 .21 .22 .21 .21 .22 .21 .21 .22 .21 .21 .21 .22 .21 .22 .21 .21 .21 .22 .21 .21 .21 .21 .21 .22 .21 .21 .21 .22 .21 .22 .21 .22 .21 .22 .21 .22 .22 .21 .22 .22 <t< td=""><td>Negalive</td><td>1.00</td><td>07</td><td></td><td></td></t<>	Negalive	1.00	07		
AcAr physical classification system 1.00 Patient with patient 1.08 (0.38–3.07) .88 Patient with severe systemic disease 1.71 (0.36–8.15) .50 Body mass index (kg/m²) -25] 1.00 1.00 _25-30] 0.19 (0.05–0.76) .02 0.17 (0.03–0.96) .045 (30– 0.81 (0.25–2.63) .72 1.40 (0.31–6.24) .66 History of benign breast disease 1.00 .00 .66 No 1.00 .66 .66 Family history of any cancer 1.00 .66 .66 Family history of any cancer 1.00 .66 .66 Family history of any cancer .00 .66 .66	PUSILIVE	0.42 (0.09–1.94)	.27		
Normal nearly patent 1.00 Patient with mild systemic disease 1.08 (0.38–3.07) .88 Patient with severe systemic disease 1.71 (0.36–8.15) .50 Body mass index (kg/m ²) -25] 1.00 1.00 -25] 0.19 (0.05–0.76) .02 0.17 (0.03–0.96) .045 (30– 0.81 (0.25–2.63) .72 1.40 (0.31–6.24) .66 History of benign breast disease 1.00 .66 .66 No 1.00 .66 .66 Family history of any cancer 1.00 .66 .66 Family history of any cancer .069 (0.14–3.45) .66 .66 Family history of any cancer .047 (0.17–1.31) .15 .15	Normal booltby nationt	1.00			
Patient with with with severe systemic disease 1.00 (0.00-0.07) 1.00 Patient with severe systemic disease 1.71 (0.36-8.15) .50 Body mass index (kg/m ²) -25] 1.00 1.00 -25] 0.19 (0.05-0.76) .02 0.17 (0.03-0.96) .045 (30- 0.81 (0.25-2.63) .72 1.40 (0.31-6.24) .66 History of benign breast disease .00 .00 .66 No 1.00 .48 .48 Marmography screening within two years .069 (0.14-3.45) .66 Family history of any cancer .00 .00 No 1.00 .00 .66 Family history of any cancer .069 (0.14-3.45) .66 Family history of any cancer .00 .00 No 0.69 (0.14-3.45) .66	Patient with mild evetemic disease	1.00	88		
Product with evolve systemic disease 1.77 (0.03–0.10) 1.00 Body mass index (kg/m ²) -25] 1.00 1.00 (25–30] 0.19 (0.05–0.76) .02 0.17 (0.03–0.96) .045 (30– 0.81 (0.25–2.63) .72 1.40 (0.31–6.24) .66 History of benign breast disease .00 .25 .66 No 1.00 .48 Mammography screening within two years .66 Family history of any cancer .069 (0.14–3.45) .66 Family history of any cancer .00 .20 No 1.00 .25 Yes 0.69 (0.14–3.45) .66	Patient with severe systemic disease	1 71 (0 36-8 15)	.00		
-25] 1.00 1.00 (25–30] 0.19 (0.05–0.76) .02 0.17 (0.03–0.96) .045 (30– 0.81 (0.25–2.63) .72 1.40 (0.31–6.24) .66 History of benign breast disease .00 .25 .66 No 1.00 .48 Mammography screening within two years .48 No 1.00 .48 Yes 0.69 (0.14–3.45) .66 Family history of any cancer .00 .20 No 1.00 .20 Yes 0.69 (0.14–3.45) .66 Family history of any cancer .20 .20 No 1.00 .20 Yes 0.67 (0.17–1.31) .15	Body mass index (kg/m ²)	1.71 (0.30–0.13)	.00		
1.00 1.00 1.00 (25–30] 0.19 (0.05–0.76) .02 0.17 (0.03–0.96) .045 (30– 0.81 (0.25–2.63) .72 1.40 (0.31–6.24) .66 History of benign breast disease 1.00 Yes 1.89 (0.32–11.14) .48 Mammography screening within two years 1.00 Yes 0.69 (0.14–3.45) .66 Family history of any cancer 1.00 Yes 0.69 (0.14–3.45) .66 Family history of any cancer 1.00 Yes 0.69 (0.14–3.45) .66	-25]	1.00		1.00	
(30- 0.10 (0.00 0.10) .02 0.11 (0.00 0.00) .040 History of benign breast disease 0.81 (0.25-2.63) .72 1.40 (0.31-6.24) .66 No 1.00 .48 Mammography screening within two years .48 No 1.00 Yes 0.69 (0.14-3.45) .66 Family history of any cancer 1.00 Yes 0.47 (0.17-1.31) .15	(25_30)	0.19 (0.05-0.76)	02	0.17 (0.03-0.96)	045
History of benign breast disease 1.00 Yes 1.89 (0.32–11.14) Mammography screening within two years No Yes 0.69 (0.14–3.45) .66 Family history of any cancer No Yes 0.47 (0.17–1.31) .15	(30-	0.81 (0.25–2.63)	.02	1 40 (0 31-6 24)	66
No 1.00 Yes 1.89 (0.32–11.14) .48 Mammography screening within two years .00 Yes 0.69 (0.14–3.45) .66 Family history of any cancer .00 Yes 0.69 (0.14–3.45) .66 Family history of any cancer .00 Yes 0.47 (0.17–1.31) .15	History of benign breast disease	0.01 (0.20 2.00)		1.10 (0.01 0.2)	.00
Yes 1.89 (0.32–11.14) .48 Mammography screening within two years .48 No 1.00 Yes 0.69 (0.14–3.45) Family history of any cancer .66 Faxily history of any cancer 1.00 Yes 0.47 (0.17–1.31) Yes 0.47 (0.17–1.31)	No	1.00			
Mamography screening within two years 1.00 No 1.00 Yes 0.69 (0.14–3.45) .66 Family history of any cancer 1.00 Yes 0.47 (0.17–1.31) .15	Yes	1.89 (0.32–11.14)	.48		
No 1.00 Yes 0.69 (0.14–3.45) Family history of any cancer .66 No 1.00 Yes 0.47 (0.17–1.31) .15	Mammography screening within two years		110		
Yes 0.69 (0.14–3.45) .66 Family history of any cancer 1.00 1.00 Yes 0.47 (0.17–1.31) .15	No	1.00			
Family history of any cancer 1.00 No 1.00 Yes 0.47 (0.17–1.31) .15	Yes	0.69 (0.14–3.45)	.66		
No 1.00 Yes 0.47 (0.17–1.31) .15	Family history of any cancer	(
Yes 0.47 (0.17–1.31) .15	No	1.00			
	Yes	0.47 (0.17-1.31)	.15		

the three groups according to length of patient interval and evaluated whether there was a trend of increased proportion of advanced cancer in these three groups with the Stata command "*nptrend*". Second, we constructed a logistic regression model with length of patient interval as the primary independent variable and advanced stage of cancer as the dependent variable. We also considered other sociodemographic and clinical characteristics as adjusting variables, using the backward stepwise variable selection method (inclusion criteria, P < .1). We used Stata IC15.0 to conduct these two analyses. We obtained ethical clearance from the Ethics Committee at MMGH.

3. Results

A flow of patient selection and key patient characteristics are described elsewhere.^[9] In summary, of 131 patients who visited the study site during the study period, 97 were symptomatic patients (50 or younger: 16 (16.5%), 51–64: 33 (34.0%), older than 65: 48 (49.5%)), and all of them were considered in the following analysis. Of the 97 patients, the proportion of patients with a patient interval of less than three months, three to twelve months, and twelve months or above was 70.1% (68), 11.3% (11), and 18.6% (18), respectively. Similarly, the proportion of anatomic stages 0, I, II, III, and IV was 5.2% (5), 29.9% (29), 43.3% (42), 14.4% (14), and 7.2% (7), respectively.

Figure 1 shows the association between patient interval and advanced stage diagnosis. The proportion of breast cancer patients diagnosed with advanced stage disease was 10.3% (7/68), 18.2% (2/11), and 66.7% (12/18) in patients with a patient interval of less than three months, three to twelve months, and twelve months or longer (*P* for trend < .001), respectively.

Table 1 shows the findings of univariate and multivariate logistic regression analyses for advanced cancer. Adjusting for other covariates, the patients with a patient interval of twelve months or longer had higher odds of being diagnosed with advanced cancer when compared to those with a patient interval of less than three months (odds ratio: 22.77; 95% confidence interval: 5.19-99.82; P < .001).

4. Discussion

In this study, we found that prolonged patient intervals was associated with advanced stage diagnosis among symptomatic but undiagnosed breast cancer patients in the area struck by the 2011 Fukushima triple disaster. In particular, in patients with a delay of 12 months or longer, two-thirds of the patients were diagnosed with advanced cancer. This result is consistent with previous studies,^[16] demonstrating the importance of timely medical consultation even in the aftermath of disasters and/or other crises.

This observation has significant clinical implications, given the findings of our previous study, which analyzed associations between prolonged patient interval and advanced-stage diagnosis among breast cancer patients in the same setting following the triple disaster.^[19] Surprisingly, the proportion of patients with advanced cancer decreased as the interval from initial medical consultation to treatment inception was prolonged, which is totally opposite from the present finding. A plausible explanation for this difference is the involvement of healthcare professionals in the process following the initial medical consultation. Namely, healthcare professionals can triage new breast cancer patients and start treatment, particularly for those with urgent medical conditions.^[19]

In this regard, it is imperative to further enhance awareness of breast cancer symptoms among undiagnosed symptomatic breast cancer patients and the general public so that patients can accurately realize the severity of their symptoms and so that family members and friends can urge them to schedule their initial consultation. To this end, we believe it is necessary to combine both a population approach and a high-risk approach. For the population approach, it is important to motivate media outlets and local municipalities to prepare articles and programs to raise awareness about the importance of timely medical consultation in breast cancer. We lobbied various media outlets when our previous paper^[9] showed an increased delay in medical consultation among breast cancer patients after the disaster, and it was featured in numerous newspaper articles in Japan. For the high-risk approach, it is important for community health workers to individually approach women with reduced family and social support.

There are several limitations in this study, including small sample size, single disaster and institutional assessment, and use of surrogate outcomes of survival prospects. However, it is often difficult to conduct a large-scale study with robust outcome measures in disaster aftermaths. Further, every disaster is unique, and generalizability is a concept that is difficult to achieve in disaster studies. In this regard, it is important to accumulate small-sized evidence on various health risks after disasters.

In conclusion, a delayed initial medical consultation was associated with advanced stage diagnosis among patients with undiagnosed symptomatic breast cancer in the area affected by the 2011 triple disaster in Fukushima, Japan. To mitigate health issues, both population and high-risk approaches should be combined, and awareness of timely medical consultation should be further enhanced, in and beyond the area affected by the 2011 Fukushima triple disaster. The health implications of interrupted cancer care have become apparent during the current COVID-19 pandemic.^[20] The cancer lessons of the 2011 Fukushima triple disaster should be widely shared in the global medical and public health communities.

Author contributions

Conceptualization: Akihiko Ozaki, Sawano Toyoaki, Manabu Tsukada, Yuki Shimada, Ayumu Kawamoto, Jiwei Wang, Divya Bhandari, Masaharu Tsubokura, Hiromichi Ohira.

Writing – review & editing: Akihiko Ozaki, Sawano Toyoaki, Manabu Tsukada, Yuki Shimada, Ayumu Kawamoto, Jiwei Wang, Divya Bhandari, Masaharu Tsubokura, Hiromichi Ohira.

References

- American Cancer Society. Breast Cancer Facts & Figures 2019–2020 [online]. 2019. Available at: https://www.cancer.org/content/dam/can cer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-fig ures/breast-cancer-facts-and-figures-2019-2020.pdf. Accessed July 4, 2021.
- [2] Eurostat. Breast cancer screening differs among Member States [online]. 2020. Available at: https://ec.europa.eu/eurostat/web/products-eurostatnews/-/DDN-20200109-1. Accessed July 4, 2021.
- [3] Japan Breast Cancer Society. National breast cancer patient registry survey report in 2017 [in Japanese]. Tokyo.
- [4] Unger-Saldana K, Infante-Castaneda CB. Breast cancer delay: a grounded model of help-seeking behaviour. Soc Sci Med 2011;72: 1096–104.
- [5] Khakbazan Z, Taghipour A, Latifnejad Roudsari R, et al. Help seeking behavior of women with self-discovered breast cancer symptoms: a metaethnographic synthesis of patient delay. PLoS One 2014;9:e110262.
- [6] Ramirez AJ, Westcombe AM, Burgess CC, et al. Factors predicting delayed presentation of symptomatic breast cancer: a systematic review. Lancet 1999;353:1127–31.
- [7] Burgess C, Hunter MS, Ramirez AJ. A qualitative study of delay among women reporting symptoms of breast cancer. Br J Gen Pract 2001; 51:967–71.
- [8] Ozaki A, Sawano T, Saito H, et al. Will initial consultation patterns among undiagnosed cancer patients be the same after this COVID-19 pandemic? Experiences from the 2011 triple disaster in Fukushima, Japan J Glob Health 2020;10:20343.
- [9] Ozaki A, Nomura S, Leppold C, et al. Breast cancer patient delay in Fukushima, Japan following the 2011 triple disaster: a long-term retrospective study. BMC Cancer 2017;17:423.

- [10] Morita T, Nomura S, Furutani T, et al. Demographic transition and factors associated with remaining in place after the 2011 Fukushima nuclear disaster and related evacuation orders. PLoS One 2018;13: e0194134.
- [11] Ozaki A, Leppold C, Tsubokura M, et al. Social isolation and cancer management after the 2011 triple disaster in Fukushima, Japan: a case report of breast cancer with patient and provider delay. Medicine (Baltimore) 2016;95:e4027.
- [12] Ozaki A, Tsubokura M, Leppold C, et al. The importance of family caregiving to achieving palliative care at home: a case report of end-of-life breast cancer in an area struck by the 2011 Fukushima nuclear crisis: a case report. Medicine (Baltimore) 2017;96:e8721.
- [13] Weiss A, Chavez-MacGregor M, Lichtensztajn DY, et al. Validation study of the American Joint Committee on cancer eighth edition prognostic stage compared with the anatomic stage in breast cancer. JAMA Oncol 2018;4:203–9.
- [14] National Cancer Center. Survival prospects of cancer patients in Japan [in Japanese] [online]. 2019. Available at: https://ganjoho.jp/reg_stat/ statistics/brochure/hosp_c_reg_surv.html. Accessed August 23, 2020.

- [15] Unger-Saldana K. Challenges to the early diagnosis and treatment of breast cancer in developing countries. World J Clin Oncol 2014;5: 465–77.
- [16] Richards MA, Westcombe AM, Love SB, et al. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 1999;353:1119–26.
- [17] Dye TD, Bogale S, Hobden C, et al. Experience of initial symptoms of breast cancer and triggers for action in Ethiopia. Int J Breast Cancer 2012;2012:908547.
- [18] Koh J, Kim MJ. Introduction of a new staging system of breast cancer for radiologists: an emphasis on the prognostic stage. Korean J Radiol 2019;20:69–82.
- [19] Ozaki A, Nomura S, Leppold C, et al. Breast cancer provider interval length in Fukushima, Japan, after the 2011 triple disaster: a long-term retrospective study. Clin Breast Cancer 2020;20:e127–50.
- [20] Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol 2020;21: 1023–34.